Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
The Nemours Foundation has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners, but are both housed within 1 distinct art unit. This suggests a focused technical scope for the company's current patent applications.
DEAL, DAVID R is the busiest examiner, currently overseeing 1 pending office action. This is one of the 2 pending office actions currently active. Because multiple distinct examiners are working within 1 art unit, the applicant should look for consistent application of biotechnology examination standards across both cases.
The small number of pending actions allows for a highly attentive prosecution approach. With 2 distinct examiners involved, the applicant can compare different approaches to the company's technical claims. The concentration in 1 distinct art unit allows for a unified strategy regarding technical arguments and prior art interpretations. This focus helps in maintaining a cohesive narrative across all pending applications in the portfolio. The applicant can focus on building a consistent body of evidence that satisfies the specific requirements of this administrative group.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DEAL, DAVID R | 1 | 83.5% | +12.1% |
| YU, DAVID TUYANG | 1 | 100.0% | +0.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18368737 | COMPOSITIONS AND METHODS OF TREATMENT OF TUMORS EXPRESSING PUTATIVE ZIKA VIRUS RECEPTOR PROTEINS | YU, DAVID TUYANG | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18792224 | KINK-REDUCING IV LINES AND EXTENSION SETS | DEAL, DAVID R | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18792224 | KINK-REDUCING IV LINES AND EXTENSION SETS | DEAL, DAVID R | — |
| Art Unit | Apps |
|---|---|
| 1635 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18792224 | KINK-REDUCING IV LINES AND EXTENSION SETS | DEAL, DAVID R | — | §102§103 | Non-Final OA | — | Pending | Aug 01, 2024 |
| 18368737 | COMPOSITIONS AND METHODS OF TREATMENT OF TUMORS EXPRESSING PUTATIVE ZIKA VIRUS RECEPTOR PROTEINS | YU, DAVID TUYANG | 1635 | §103DP | Final Rejection | — | Pending | Sep 15, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial